Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Senshio Approved in Europe for Treatment of Symptomatic Vulvar, Vaginal Atrophy: Shionogi
January 26, 2015
- Takara Bio to Initiate Clinical Trial for Anticancer Agent HF10 in Japan
January 26, 2015
- US FDA Advisory Committee Recommends Approval of Astellas’s Azole Antifungal Agent
January 26, 2015
- Nihon Chouzai Confident of Continuing Early Price Settlements
January 23, 2015
- Open Tenders Good Example of Early Price Settlements: Qol Exec
January 22, 2015
- Lifestyle Disease-Related Medical Spending Must Be Pruned: Nobelpharma Pres.
January 22, 2015
- Medical System Network President Calls for Scrapping Fee Cut Rule
January 21, 2015
- Sakura Finetek Japan to Participate in Cervical Cancer Screening Project in Kazakhstan
January 21, 2015
- Meiji Seika Pharma Licenses Darinaparsin from Solasia Pharma in Japan
January 20, 2015
- Sanofi Launches Allegra Dry Syrup for Pediatric Patients Aged 6 Months and Older
January 20, 2015
- Pharma Bigwigs Stress Importance of Early Patent Strategies
January 19, 2015
- Foreign-Affiliated Pharmas Looking to Make “Sure Investments” to Avoid Risk of Discontinued Development: PhRMA Official
January 19, 2015
- Mr Plata Named as AbbVie G.K.’s New President
January 19, 2015
- Belsomra Most Heavily Pitched Drug in November: Anterio Ranking
January 16, 2015
- Toyama Chemical Commences PII Study for Solithromycin in Japan
January 16, 2015
- Sumitomo Dainippon Files Latuda Patent Infringement Lawsuits in US against 3 Pharmas
January 16, 2015
- Otsuka Completes Acquisition of Avanir for US$3.56 Billion
January 15, 2015
- Lantus Biosimilar Approved: Eli Lilly Japan, NBI
January 15, 2015
- Takeda to Roll Out Colcrys AG in US
January 14, 2015
- Meiji, Roche, Fedora Tie Up for Development, Commercialization of Beta-Lactamase Inhibitor
January 14, 2015
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…